Evidence map›Paper›PMID 38281771›Full record

ArticleBiometrics2024

Multiple augmented reduced rank regression for pan-cancer analysis.

Jiuzhou Wang, Eric F Lock

Abstract read
In one paragraph

Article in Biometrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Integrative Analysis of Multimodal Omics Data.Annual review of statistics and its application · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiuzhou WangDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN 55414, United States.ORCID 0000-0003-0703-7255
Eric F LockDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN 55414, United States.ORCID 0000-0003-4663-2356

Funding

Identifying Biomarkers from Multi-source, Multi-way DataR01GM130622 · NIGMS · UNIVERSITY OF MINNESOTA · PI LOCK, ERIC F · 2019 to 2023
$1.5M
NIGMS NIH HHS R01 GM130622NIH HHS R01-GM130622
6 · The paper itself

Abstract

Statistical approaches that successfully combine multiple datasets are more powerful, efficient, and scientifically informative than separate analyses. To address variation architectures correctly and comprehensively for high-dimensional data across multiple sample sets (ie, cohorts), we propose multiple augmented reduced rank regression (maRRR), a flexible matrix regression and factorization method to concurrently learn both covariate-driven and auxiliary structured variations. We consider a structured nuclear norm objective that is motivated by random matrix theory, in which the regression or factorization terms may be shared or specific to any number of cohorts. Our framework subsumes several existing methods, such as reduced rank regression and unsupervised multimatrix factorization approaches, and includes a promising novel approach to regression and factorization of a single dataset (aRRR) as a special case. Simulations demonstrate substantial gains in power from combining multiple datasets, and from parsimoniously accounting for all structured variations. We apply maRRR to gene expression data from multiple cancer types (ie, pan-cancer) from The Cancer Genome Atlas, with somatic mutations as covariates. The method performs well with respect to prediction and imputation of held-out data, and provides new insights into mutation-driven and auxiliary variations that are shared or specific to certain cancer types.

Indexed as

NeoplasmsHumansMultivariate Analysiscancer genomicsdata integrationlow rank matrix factorizationmissing data imputationnuclear normreduced rank regression

Identifiers

PMID38281771
PMCPMC10826883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.